SSSW(SH:688399)2020-10-28 16:00Financial Performance - Operating income for the first nine months surged by 477.43% to CNY 1,100,656,632.20[6] - Net profit attributable to shareholders increased by 1,068.91% to CNY 581,793,307.96[6] - Net profit after deducting non-recurring gains and losses increased by 1,060.39% to CNY 553,933,914.61[6] - Basic and diluted earnings per share reached CNY 9.93, up 778.76% compared to the previous year[6] - The company reported a net profit increase of 293.85%, with retained earnings reaching ¥544,075,671.90 compared to ¥138,142,363.94 in the previous year[14] - The net profit for Q3 2020 was CNY 581,793,307.96, representing a 1440.78% increase from CNY 49,772,187.04 in the same period last year, attributed to the surge in COVID-19 product sales[15] - The total profit for Q3 2020 was ¥323.90 million, compared to ¥22.23 million in Q3 2019, reflecting an increase of 1,453.5%[31] Assets and Liabilities - Total assets increased by 62.92% year-on-year, reaching CNY 1,880,702,260.26[6] - The total assets as of September 30, 2020, amounted to CNY 1,435,054,620.07, compared to CNY 890,451,469.04 at the end of 2019, indicating substantial growth in asset base[20] - Total liabilities increased by 239.87% to ¥453,979,483.43 from ¥133,572,994.95, driven by changes in both current and non-current liabilities[14] - Current liabilities rose significantly to ¥361,535,704.90 from ¥94,232,251.97, an increase of approximately 283%[22] - Owner's equity increased to ¥1,426,722,776.83 from ¥1,020,789,468.87, showing a growth of about 39.7%[22] Cash Flow - Net cash flow from operating activities rose by 889.14% to CNY 466,178,480.17[6] - Cash and cash equivalents at the end of Q3 2020 totaled CNY 242,360,125.64, a 914.59% increase from CNY 23,887,396.28 at the end of Q3 2019, driven by improved cash flow from operating activities[16] - The cash flow from operating activities for the first three quarters of 2020 was ¥466,178,480.17, compared to ¥47,129,791.91 in the first three quarters of 2019, indicating a substantial increase[37] - The company reported a cash inflow from operating activities of RMB 1,132,665,834.10 for the first three quarters of 2020, a substantial increase from RMB 205,653,025.32 in the same period of 2019, representing a growth of approximately 450.5%[41] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,496[10] - The top shareholder, Shaoxing RunKang Biological Medicine Equity Investment Partnership, holds 26.61% of shares[10] Research and Development - Research and development expenses increased to CNY 43,842,961.10, up 78.11% from CNY 24,615,181.58 in the previous year, reflecting the company's commitment to enhancing R&D efforts[15] - The company's research and development expenses for the first three quarters of 2020 amounted to ¥44,387,789.20, an increase from ¥25,001,354.52 in the same period of 2019[35] Inventory and Sales - Inventory levels surged by 847.82% to ¥179,886,873.27 from ¥18,978,925.77, primarily due to stockpiling of COVID-19 products[13] - Total revenue from sales of goods and services in Q3 2020 was CNY 1,044,745,780.32, a 451.27% increase from CNY 189,516,938.50 in Q3 2019, mainly due to the rise in sales of COVID-19 products[16] - The company recorded a significant increase in sales expenses, totaling CNY 147,922,753.67, up 129.04% from CNY 64,583,679.59, largely due to increased sales bonuses related to COVID-19 products[15] Government Support - The company received government subsidies, contributing to a 132.26% increase in deferred income to ¥91,127,079.76[14] - The company reported a total of CNY 14,306,543.00 in other income, a 335.77% increase from CNY 3,283,022.51, primarily due to government subsidies received[15] Future Outlook - The company expects a significant increase in net profit for the full year 2020 compared to 2019, although specific growth percentages remain uncertain due to unpredictable factors affecting operations[17]